Skip to main content

ORIGINAL RESEARCH article

Front. Endocrinol.
Sec. Systems Endocrinology
Volume 15 - 2024 | doi: 10.3389/fendo.2024.1375896
This article is part of the Research Topic Serum Metabolites in Diagnostics and Therapeutics View all 10 articles

From serum metabolites to the gut : revealing metabolic clues to susceptibility to subtypes of Crohn's disease and ulcerative colitis

Provisionally accepted
Fan LI Fan LI Zhaodi Wang Zhaodi Wang Tongyu Tang Tongyu Tang Qi Zhao Qi Zhao Zhi Wang Zhi Wang Xiaoping Han Xiaoping Han Zifeng Xu Zifeng Xu Yu Chang Yu Chang Hongyan Li Hongyan Li Sileng Hu Sileng Hu 婵娇 于 婵娇 于 Shiyu Chang Shiyu Chang Yue Liu Yue Liu Yuqin Li Yuqin Li *
  • First Affiliated Hospital of Jilin University, Changchun, Jilin Province, China

The final, formatted version of the article will be published soon.

    Background and Aims: Inflammatory bowel disease (IBD) is a common chronic inflammatory bowel disease characterized by diarrhea and abdominal pain. Recently human metabolites have been found to help explain the underlying biological mechanisms of diseases of the intestinal system, so we aimed to assess the causal relationship between human blood metabolites and susceptibility to IBD subtypes.We selected a genome-wide association study (GWAS) of 275 metabolites as the exposure factor, and the GWAS dataset of 10 IBD subtypes as the outcome, followed by univariate and multivariate analyses using a two-sample Mendelian randomization study (MR) to study the causal relationship between exposure and outcome, respectively. A series of sensitivity analyses were also performed to ensure the robustness of the results.Results: A total of 107 metabolites were found to be causally associated on univariate analysis after correcting for false discovery rate (FDR), and a total of 9 metabolites were found to be significantly causally associated on subsequent multivariate and sensitivity analyses. In addition we found causal associations between 7 metabolite pathways and 6 IBD subtypes.Our study confirms that blood metabolites and certain metabolic pathways are causally associated with the development of IBD subtypes and their parenteral manifestations. The exploration of the mechanisms of novel blood metabolites on IBD may provide new therapeutic ideas for IBD patients.

    Keywords: Crohn's disease, inflammatory bowel disease, ulcerative colitis, metabolite, metabolic pathway, Mendelian randomization

    Received: 01 Feb 2024; Accepted: 23 Jul 2024.

    Copyright: © 2024 LI, Wang, Tang, Zhao, Wang, Han, Xu, Chang, Li, Hu, 于, Chang, Liu and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Yuqin Li, First Affiliated Hospital of Jilin University, Changchun, 130012, Jilin Province, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.